Cefepime (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cefepime" in English language version.

refsWebsite

Global rank English rank

6nih.gov

4^th place

5doi.org

2^nd place

3web.archive.org

1^st place

1fda.gov

447^th place

338^th place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1toku-e.com

low place

1e-jnc.org

low place

1worldcat.org

5^th place

1acponline.org

low place

acponline.org

acphospitalist.acponline.org

Weber C. "Cefepime-induced neurotoxicity". acphospitalist.acponline.org. Retrieved 20 March 2025.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495. Archived from the original on 19 June 2021. Retrieved 19 September 2020.

doi.org

Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (May 2007). "Efficacy and safety of cefepime: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 7 (5): 338–348. doi:10.1016/S1473-3099(07)70109-3. PMID 17448937.
Chapman TM, Perry CM (2003). "Cefepime: a review of its use in the management of hospitalized patients with pneumonia". American Journal of Respiratory Medicine. 2 (1): 75–107. doi:10.1007/bf03256641. PMID 14720024.
Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS (2017). "Characterizing Cefepime Neurotoxicity: A Systematic Review". Open Forum Infectious Diseases. 4 (4): ofx170. doi:10.1093/ofid/ofx170. PMC 5639733. PMID 29071284.
Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. (November 2017). "Cefepime-induced neurotoxicity: a systematic review". Critical Care. 21 (1): 276. doi:10.1186/s13054-017-1856-1. PMC 5686900. PMID 29137682.
Lee SJ (24 December 2019). "Cefepime-induced neurotoxicity". Journal of Neurocritical Care. 12 (2): 74–84. doi:10.18700/jnc.190109. ISSN 2005-0348.

e-jnc.org

Lee SJ (24 December 2019). "Cefepime-induced neurotoxicity". Journal of Neurocritical Care. 12 (2): 74–84. doi:10.18700/jnc.190109. ISSN 2005-0348.

fda.gov

"FDA Alert: Cefepime (marketed as Maxipime)". Information for Healthcare Professionals. Food and Drug Administration. Archived from the original on 2 November 2017. Retrieved 2 August 2009.

handle.net

hdl.handle.net

World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.

nih.gov

pubmed.ncbi.nlm.nih.gov

Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (May 2007). "Efficacy and safety of cefepime: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 7 (5): 338–348. doi:10.1016/S1473-3099(07)70109-3. PMID 17448937.
Chapman TM, Perry CM (2003). "Cefepime: a review of its use in the management of hospitalized patients with pneumonia". American Journal of Respiratory Medicine. 2 (1): 75–107. doi:10.1007/bf03256641. PMID 14720024.
Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS (2017). "Characterizing Cefepime Neurotoxicity: A Systematic Review". Open Forum Infectious Diseases. 4 (4): ofx170. doi:10.1093/ofid/ofx170. PMC 5639733. PMID 29071284.
Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. (November 2017). "Cefepime-induced neurotoxicity: a systematic review". Critical Care. 21 (1): 276. doi:10.1186/s13054-017-1856-1. PMC 5686900. PMID 29137682.

ncbi.nlm.nih.gov

Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS (2017). "Characterizing Cefepime Neurotoxicity: A Systematic Review". Open Forum Infectious Diseases. 4 (4): ofx170. doi:10.1093/ofid/ofx170. PMC 5639733. PMID 29071284.
Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. (November 2017). "Cefepime-induced neurotoxicity: a systematic review". Critical Care. 21 (1): 276. doi:10.1186/s13054-017-1856-1. PMC 5686900. PMID 29137682.

toku-e.com

"Cefepime Susceptibility and Concentration Range (μg/ml) Minimum Inhibitory Concentration (MIC) Data" (PDF). The Antimicrobial Index. toku-e.com. Archived from the original (PDF) on 1 November 2018.

web.archive.org

"FDA Alert: Cefepime (marketed as Maxipime)". Information for Healthcare Professionals. Food and Drug Administration. Archived from the original on 2 November 2017. Retrieved 2 August 2009.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495. Archived from the original on 19 June 2021. Retrieved 19 September 2020.
"Cefepime Susceptibility and Concentration Range (μg/ml) Minimum Inhibitory Concentration (MIC) Data" (PDF). The Antimicrobial Index. toku-e.com. Archived from the original (PDF) on 1 November 2018.

worldcat.org

search.worldcat.org

Lee SJ (24 December 2019). "Cefepime-induced neurotoxicity". Journal of Neurocritical Care. 12 (2): 74–84. doi:10.18700/jnc.190109. ISSN 2005-0348.